Stifel Maintains Hold on ALX Oncology Holdings, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino maintains a Hold rating on ALX Oncology Holdings (NASDAQ:ALXO) but lowers the price target from $14 to $5.
August 01, 2024 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stifel analyst Bradley Canino maintains a Hold rating on ALX Oncology Holdings but significantly lowers the price target from $14 to $5.
The significant reduction in the price target from $14 to $5 by Stifel suggests a negative outlook on ALX Oncology Holdings' future performance. This is likely to put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100